Frédérique Lussier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Frédérique Lussier has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Tremblay
Institut de Pharmacologie de Sherbrooke, Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada
1 shared publication - Amirmohammad Ranjbaran
Institut de Pharmacologie de Sherbrooke, Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada
1 shared publication - Brian J. Holleran
Institut de Pharmacologie de Sherbrooke, Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada
1 shared publication - Félix Bélair
Institut de Pharmacologie de Sherbrooke, Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada
1 shared publication - Ines Robberechts
Research Group of Organic Chemistry, Departments of Chemistry and Bioengineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium
1 shared publication - Isabelle Brochu
Institut de Pharmacologie de Sherbrooke, Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada
1 shared publication
Latest Publications
- Open Access
- 11 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119488
Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo
- 11 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119488
Open AccessDual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo